Alkermes (ALKS)
(Real Time Quote from BATS)
$28.32 USD
+0.95 (3.47%)
Updated Oct 11, 2024 11:10 AM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
ALKS 28.32 +0.95(3.47%)
Will ALKS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALKS
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
Here's Why Alkermes (ALKS) is a Strong Growth Stock
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
Here's Why Alkermes (ALKS) is a Strong Value Stock
Other News for ALKS
Alkermes (ALKS) Receives a Buy from Jefferies
TD Cowen Sticks to Their Buy Rating for Alkermes (ALKS)
Alkermes (ALKS) Gets a Buy from Piper Sandler
Decoding 7 Analyst Evaluations For Alkermes
Alkermes’s Promising Orexin Drug Development Positions Company for Market Leadership